NDAINTRAVENOUSSOLUTION
Approved
Jun 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
VAZCULEP (phenylephrine hydrochloride) by Aspiro Therapeutics is α-1 adrenergic receptor agonist. Approved for hypotension, nasal congestion, allergic rhinitis and 1 more indications. First approved in 2014.
Drug data last refreshed 19h ago
Mechanism of Action
α-1 adrenergic receptor agonist.
Indications (4)
Worked on VAZCULEP at Aspiro Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.